|
[1]Chinese Socity of Hepatology and Chinese Society of Infection Diseases, Chinese Medical Association.The guideline of prevention and treatment for hepatitis C:a 2015 updated[J].J Clin Hepatol, 2015, 31 (12) :1961-1979. (in Chinese) 中华医学会肝病学分会, 中华医学会感染病学分会.丙型肝炎防治指南 (2015年更新版) [J].临床肝胆病杂志, 2015, 31 (12) :1961-1979.
|
|
[2]TOYODA H, TADA T, TACHI Y, et al.Liver fibrosis indices for identifying patients at low risk of developing hepatocellular carcinoma after eradication of HCV[J].Antivir Ther, 2016.[Epub ahead of print]
|
|
[3]KOBAYASHI M, SUZUKI F, FUJIYAMA S, et al.Sustained virologic response by direct antiviral agents reduces the incidence of hepatocellular carcinoma in patients with HCV infection[J].J Med Virol, 2016.[Epub ahead of print]
|
|
[4]HEDENSTIERNA M, NANGARHARI A, WEILAND O, et al.Diabetes and cirrhosis are risk factors for hepatocellular carcinoma after successful treatment of chronic hepatitis C[J].Clin Infect Dis, 2016, 63 (6) :723-729.
|
|
[5]YANG JD, AHMED MOHAMMED H, CVINAR JL, et al.Diabetes mellitus heightens the risk of hepatocellular carcinoma except in patients with hepatitis C cirrhosis[J].Am J Gastroenterol, 2016.[Epub ahead of print]
|
|
[6]WU CK, CHANG KC, HUNG CH, et al.Dynamicα-fetoprotein, platelets and AST-to-platelet ratio index predict hepatocellular carcinoma in chronic hepatitis C patients with sustained virological response after antiviral therapy[J].J Antimicrob Chemother, 2016, 71 (7) :1943-1947.
|
|
[7]NAGAOKI Y, AIKATA H, NAKANO N, et al.Development of hepatocellular carcinoma in patients with hepatitis C virus infection who achieved sustained virological response following interferon therapy:a large-scale, long-term cohort study[J].J Gastroenterol Hepatol, 2016, 31 (5) :1009-1015.
|
|
[8]WU CK, CHANG KC, TSENG PL, et al.Comparison of therapeutic response and clinical outcome between HCV patients with normal and abnormal alanine transaminase levels[J].PLoS One, 2016, 11 (3) :e0142378.
|
|
[9]TOYODA H, KUMADA T, TADA T, et al.Risk factors of hepatocellular carcinoma development in non-cirrhotic patients with sustained virologic response for chronic hepatitis C virus infection[J].J Gastroenterol Hepatol, 2015, 30 (7) :1183-1189.
|
|
[10]QU LS, CHEN H, KUAI XL, et al.Effects of interferon therapy on development of hepatocellular carcinoma in patients with hepatitis C-related cirrhosis:a meta-analysis of randomized controlled trials[J].Hepatol Res, 2012, 42 (8) :782-789.
|
|
[11]WATANABE S, ENOMOTO N, KOIKE K, et al.Cancer preventive effect of pegylated interferonα-2b plus ribavirin in a real-life clinical setting in Japan:PERFECT interim analysis[J].Hepatol Res, 2011, 41 (10) :955-964.
|
|
[12]KANOGAWA N, OGASAWARA S, CHIBA T, et al.Sustained virologic response achieved after curative treatment of hepatitis C virus-related hepatocellular carcinoma as an independent prognostic factor[J].J Gastroenterol Hepatol, 2015, 30 (7) :1197-1204.
|
|
[13]D'AMBROSIO R, DELLA CORTE C, COLOMBO M.Hepatocellular carcinoma in patients with a sustained response to anti-hepatitis C therapy[J].Int J Mol Sci, 2015, 16 (8) :19698-19712.
|
|
[14]ALEMAN S, RAHBIN N, WEILAND O, et al.A risk for hepatocellular carcinoma persists long-term after sustained virologic response in patients with hepatitis C-associated liver cirrhosis[J].Clin Infect Dis, 2013, 57 (2) :230-236.
|
|
[15]YOUNOSSI ZM, STEPANOVA M, NADER F, et al.Associations of chronic hepatitis C with metabolic and cardiac outcomes[J].Alimen Pharmacol Ther, 2013, 37 (6) :647-652.
|
|
[16]ELKRIEF L, CHOUINARD P, BENDERSKY N, et al.Diabetes mellitus is an independent prognostic factor for major liver-related outcomes in patients with cirrhosis and chronic hepatitis C[J].Hepatology, 2014, 60 (3) :823-831.
|
|
[17]CHANG KC, HUNG CH, LU SN, et al.A novel predictive score fo hepatocellular carcinoma development in patients with chronic hepatitis C after sustained response to pegylated interferon and ribavirin combination therapy[J].J Antimicrob Chemother, 2012, 67 (11) :2766-2772.
|
|
[18]LEE MH, YANG HI, LU SN, et al.Hepatitis C virus genotype 1b increases cumulative lifetime risk of hepatocellular carcinoma[J].Int J Cancer, 2014, 135 (5) :1119-1126.
|
|
[19]KANWAL F, KRAMER JR, ILYAS J, et al.HCV genotype 3 is associated with an increased risk of cirrhosis and hepatocellular cancer in a national sample of U.S.Veterans with HCV[J].Hepatology, 2014, 60 (1) :98-105.
|
|
[20]SHINDOH J, HASEGAWA K, TAKEMURA N, et al.Hepatitis Cviral load predicts tumor recurrence after curative resection of hepatocellular carcinoma regardless of the genotype of hepatitis C virus[J].Hepatol Int, 2014, 8 (1) :112-120.
|
|
[21]PINZONE MR, ZANGHìAM, RAPISARDA L, et al.Cirrhotic patients are still at risk of developing hepatocellular carcinoma despite Interferon-induced sustained virological response[J].Eur Rev Med Pharmacol Sci, 2014, 18 (2 Suppl) :11-15.
|
|
[22]CHEN J, HAN Y, XU C, et al.Effect of type 2 diabetes mellitus on the risk for hepatocellular carcinoma in chronic liver diseases:a meta-analysis of cohort studies[J].Eur J Cancer Prev, 2015, 24 (2) :89-99.
|
|
[23]TSUJITA E, MAEDA T, KAYASHIMA H, et al.Effect of sustained virological response to interferon therapy for hepatitis C to the hepatectomy for primary hepatocellular carcinoma[J].Hepatogastroenterology, 2015, 62 (137) :157-163.
|
|
[24]HUANG YW, WANG TC, YANG SS, et al.Increased risk of hepatocellular carcinoma in chronic hepatitis C patients with new onse diabetes:a nation-wide cohort study[J].Aliment Pharmacol T-her, 2015, 42 (7) :902-911.
|
|
[25]LI CI, CHEN HJ, LAI HC, et al.Hyperglycemia and chronic liver diseases on risk of hepatocellular carcinoma in Chinese patients with type 2 diabetes-National cohort of Taiwan Diabetes Study[J].In J Cancer, 2015, 36 (11) :2668-2679.
|
|
[26]OGAWA E, FURUSYO N, KAJIWARA E, et al.Efficacy of pegylated interferon alpha-2b and ribavirin treatment on the risk of hepatocellular carcinoma in patients with chronic hepatitis C:a prospective, multicenter study[J].J Hepatol, 2013, 58 (3) :495-501.
|
|
[27]HUANG CF, YEH ML, TSAI PC, et al.Baseline gamma-glutamyl transferase levels strongly correlate with hepatocellular carcinoma development in non-cirrhotic patients with successful hepatitis C virus eradication[J].J Hepatol, 2014, 61 (1) :67-74.
|
|
[28]REDDY A, MAY E, EHRINPREIS M, et al.Latent hepatitis B is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C[J].World J Gastroenterol, 2013, 19 (48) :9328-9333.
|
|
[29]HUANG YW, YANG SS, FU SC, et al.Increased risk of cirrhosis and its decompensation in chronic hepatitis C patients with newonset diabetes:a nationwide cohort study[J].Hepatology, 2014, 60 (3) :807-814.
|
|
[30]HUNG CH, LEE CM, WANG JH, et al.Impact of diabetes mellitus on incidence of hepatocellular carcinoma in chronic hepatitis Cpatients treated with interferon-based antiviral therapy[J].Int JCancer, 2011, 128 (10) :2344-2352.
|
|
[31]KANEDA K, UENISHI T, TAKEMURA S, et al.The influence of postoperative glycemic control on recurrence after curative resection in diabetics with hepatitis C virus-related hepatocellular carcinoma[J].J Surg Oncol, 2012, 105 (6) :606-611.
|
|
[32]NKONTCHOU G, COSSON E, AOUT M, et al.Impact of metformin on the prognosis of cirrhosis induced by viral hepatitis C in diabetic patients[J].J Clin Endocrinol Metab, 2011, 96 (8) :2601-2608.
|
|
[33]KAWAGUCHI T, TANIGUCHI E, MORITA Y, et al.Association of exogenous insulin or sulphonylurea treatment with an increased incidence of hepatoma in patients with hepatitis C virus infection[J].Liver Int, 2010, 30 (3) :479-486.
|
|
[34]HARRIS K, SMITH L.Safety and efficacy of metformin in patients with type 2 diabetes mellitus and chronic hepatitis C[J].Ann Pharmacother, 2013, 47 (10) :1348-1352.
|
|
[35]GOOSSENS N, NEGRO F.The impact of obesity and metabolic syndrome on chronic hepatitis C[J].Clin Liver Dis, 2014, 18 (1) :147-156.
|
|
[36]ADINOLFI LE, RESTIVO L, MARRONE A.The predictive value of steatosis in hepatitis C virus infection[J].Expert Rev Gastroenterol Hepatol, 2013, 7 (3) :205-213.
|
|
[37]ZAMPINO R, PISATURO MA, CIRILLO G, et al.Hepatocellular carcinoma in chronic HBV-HCV co-infection is correlated to fibrosis and disease duration[J].Ann Hepatol, 2015, 14 (1) :75-82.
|
|
[38]SARMA MP, ASIM M, MEDHI S, et al.Viral genotypes and associated risk factors of hepatocellular carcinoma in India[J].Cancer Biol Med, 2012, 9 (3) :172-181.
|
|
[39]HUNG CH, LU SN, WANG JH, et al.Sustained HCV clearance by interferon-based therapy reduces hepatocellular carcinoma in hepatitis B and C dually-infected patients[J].Antivir Ther, 2011, 16 (7) :959-968.
|
|
[40]MERCHANTE N, MERINO E, RODRGUEZ-ARRONDO F, et al.HIV/hepatitis C virus-coinfected patients who achieved sustained virological response are still at risk of developing hepatocellular carcinoma[J].AIDS, 2014, 28 (1) :41-47.
|
DownLoad: